IRICoR is very pleased to announce the appointment as of January 11, 2021 of Rémi-Martin Laberge as Vice-President, Scientific Operations and new member of IRICoR’s Management team. In this role, Dr. Laberge’s responsibilities will include ensuring, with his team, a continued follow-up of portfolio projects with support to the research teams, and identification of new opportunities in line with a balanced portfolio strategy towards targeted exit events.
Dr. Laberge brings a vast experience from both academia and industry. He co-authored over 50 scientific and patent publications, namely on a new class of agents called Senolytics currently in clinical development, that he co-discovered.
Prior to joining IRICoR, Dr. Laberge was a Principal Investigator at Unity Biotechnology [NASDAQ :UBX], a California-based clinical stage biotech company focusing on alleviating age-related diseases. He was key at building Unity’s scientific platform, as well as heading various scientific teams within Unity leading them to clinical stage assets.
Dr Laberge holds a Ph.D. from McGill University where he studied multidrug resistance in oncology and completed his post-doctoral fellowship with Dr. J. Campisi at the Buck Institute for Research on Aging in California
“I am delighted to welcome Rémi-Martin in our team. His extended expertise in drug discovery both in academia and industry in addition to his US experience are important additional assets for IRICoR’s current and future endeavors”, commented Nadine Beauger, President – Chief Executive Officer at IRICoR.